Abstract
Tilidine is one of the most widely used narcotics in Germany and Belgium. The compound’s active metabolite nortilidine easily penetrates the blood–brain barrier and activates the μ-opioid receptor. Thus far, the enzymes involved in tilidine metabolism are unknown. Therefore, the aim of our study was to identify the cytochrome P450 isozymes (CYPs) involved in N-demethylation of tilidine in vitro. We used human liver microsomes as well as recombinant CYPs to investigate the demethylation of tilidine to nortilidine and quantified nortilidine by liquid chromatography-tandem mass spectrometry. Inhibition of CYPs was quantified with commercial kits. Moreover, inhibition of ABCB1 and ABCG2 was investigated. Our results demonstrated that N-demethylation of tilidine to nortilidine followed a Michaelis–Menten kinetic with a K m value of 36 ± 13 μM and a v max value of 85 ± 18 nmol/mg/h. This metabolic step was inhibited by CYP3A4 and CYP2C19 inhibitors. Investigations with recombinant CYP3A4 and CYP2C19 confirmed that the demethylation of tilidine occurs via these two CYPs. Inhibition assays demonstrated that tilidine and nortilidine can also inhibit CYP3A4, CYP2C19, CYP2D6, ABCB1, but not ABCG2, whereas inhibition of CYP2D6 and possibly also of CYP3A4 might be clinically relevant. By calculating the metabolic clearance based on the in vitro and published in vivo data, CYP3A4 and CYP2C19 were identified as the main elimination routes of tilidine. In vivo, drug–drug interactions of tilidine with CYP3A4 or CYP2C19 inhibitors are to be anticipated, whereas substrates of CYP2C19, ABCB1, or ABCG2 will presumably not be influenced by tilidine or nortilidine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CYP:
-
cytochrome P450 isozyme
- FCS:
-
fetal calf serum
- DDD:
-
defined daily dose
- DEDC:
-
diethyldithiocarbamate
- DMSO:
-
dimethyl sulfoxide
- HLM:
-
human liver microsomes
- LC/MS/MS:
-
liquid chromatography-tandem mass spectrometry
- SD:
-
standard deviation
References
Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ (2002) The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 30:1497–1503
Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzane-Do A, Bollinger P, Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226–4233
Fröhlich M, Albermann N, Sauer A, Walter-Sack I, Haefeli WE, Weiss J (2004) In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol 68:2409–2416
Hajda JP, Jahnchen E, Oie S, Trenk D (2002) Sequential first-pass metabolism of nortilidine: the active metabolite of the synthetic opioid drug tilidine. J Clin Pharmacol 42:1257–1261
International Narcotics Control Board (2007) Narcotic drugs: estimated world requirements for 2007 and statistics for 2005 (E/INCB/2006/2). United Nations, New York
Kim RB, Wandel C, Leake B, Cvetkovic AK, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudary AK, Roden DM, Wood AJJ, Wilkinson GR (1999) Interrelationship between inhibitors and substrates of human CYP-3A and P-glycoprotein. Pharmacol Res 16:408–414
Mannel M (2004) Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Safety 27:773–797
Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42:819–850
Obach RS (2000) Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro–in vivo correlation. Drug Metab Dispos 28:1069–1076
Regenthal R, Krüger M, Richter M, Preiss R (1998) Poisoning with tilidine and naloxone: toxicokinetic and clinical observations. Hum Exp Toxicol 17:593–597
Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3–29
Schulz R, Bläsig J, Wüster M, Herz A (1978) The opiate-like action of tilidine is mediated by metabolites. Naunyn-Schiedeberg’s Arch Pharmacol 304:89–93
Seiler KU, Jähnchen E, Trenk D, Brennscheidt U, Heintz B (2001) Pharmacokinetics of tilidine in terminal renal failure. J Clin Pharmacol 41:79–84
Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD et al (1991) Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 16:249–255
Störmer E, von Moltke LL, Shader RI, Greenblatt DJ (2000) Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 1A2, 2D6, and 3A4. Drug Metab Dispos 28:1168–1175
Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J (2007) Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73:1573–1581
Sykes MJ, Sorich MK, Miners JO (2006) Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes. J Chem Inf Model 46:2661–2673
Tanaka E (1998) Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 23:403–416
Thierry C, Boeynaems JM, Paolo M (2005) Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol 506:205–208
Vollmer KO, Poisson A (1970) Human pharmacokinetics of the new potent analgesic dl-trans-2-di-methylamino-1-phenyl-cyclohex-3-en-trans-1-carboxylic acid ethyl ester hydrochloride1. Blood level and excretion with urine and feces after single oral administration of 14C-labeled substance. Arzneimittelforschung 20:992–995
Vollmer KO, Hodenberg AV (1977) Metabolism of dl-trans-2-dimethylamino-1-phenyl-cyclohex-3-ene-trans-1-carboxylic acid ester hydrochloride (Tilidine HC1). 3. Renal elimination of metabolites in the rat, dog and man. Arzneimittelforschung 27:1707–1713
Vollmer KO, Thomann P, Hengy H (1989) Pharmacokinetics of tilidine and metabolites in man. Arzneimittelforschung 39:1283–1288
Wacher VJ, Wu CY, Benet LL (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129–134
Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE (2003) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305:197–204
Weiss J, Haefeli WE (2006) Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values. Drug Metab Dispos 34:203–207
Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth TE (2007) Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59:238–245
Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211–2221.
Yu DK (1999) The contribution of P-glycoprotein to pharmacokinetic drug–drug interactions. J Clin Pharmacol 39:1203–1211
Acknowledgments
We thank Corina Mueller, Stephanie Rosenzweig, and Jutta Kocher for excellent technical assistance. Moreover, we would like to acknowledge the supply of P388/dx cells by and Dr. Dario Ballinari (Pharmacia & Upjohn, Milan, Italy), of MDCKII-BCRP by Dr. A. H. Schinkel (National Cancer Institute, Amsterdam, The Netherlands), and the financial support and the kind supply of tilidine and nortilidine by Pfizer (Karlsruhe, Germany).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weiss, J., Sawa, E., Riedel, KD. et al. In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. Naunyn-Schmied Arch Pharmacol 378, 275–282 (2008). https://doi.org/10.1007/s00210-008-0294-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-008-0294-7